2022 Compound Screening Small Molecule 
Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . million in 2022 to 12.7 With its recent award of $3.35 million by 2050.” . Focused on opportunity .
Drug Discovery World
JANUARY 26, 2023
The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at large and the pharmaceutical industry. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. However, that is not to say it was an easy year.
Expert insights. Personalized for you.
130 
Let's personalize your content